Introduction
In response to pathological stimuli such as prolonged mechanical stress or abnormal neurohumoral activation, hearts show hypertrophic growth and remodeling characterized by an increase in myocyte cell size, assembly of sarcomere proteins, interstitial fibrosis, and re-expression of fetal cardiac genes. Although the hypertrophic response is initially compensatory, it ultimately leads to heart failure, which is now a leading cause of morbidity and mortality around the world. Diverse intracellular signaling pathways, which ultimately affect nuclear factors and the regulation of gene expression, have been shown to play important roles in the pathological processes involved in cardiac remodeling (1) . Unraveling the details of these pathways should give us a better understanding of the molecular processes underlying the establishment of cardiac hypertrophy and heart failure and could ultimately lead to the discovery of novel therapeutic targets for the prevention of pathological cardiac remodeling and heart failure. In this review, we introduce our recent findings regarding the signal transduction cascades that drive transcriptional remodeling during the pathological process of heart failure.
identified as a negative-acting DNA regulatory element that prevents expression of neuronal genes in non-neuronal cell types and in undifferentiated neuronal cells (2, 3) . A transcriptional repressor, neuron-restrictive silencer factor (NRSF), also known as RE-1 silencing transcription factor (REST), binds to NRSE to exert its regulatory effects (4, 5) . We reported that NRSE is present within the transcriptional regulatory region of multiple fetal cardiac genes, such as those encoding ANP, BNP, skeletal α-actin, and fetal ion channels, and that it plays a pivotal role in the regulation of the expression of these genes in cardiac myocytes (6 -8) . The NRSE-NRSF system represses fetal cardiac gene expression in ventricular myocytes by recruiting the class I histone deacetylases (HDACs) HDAC-1 and -2, and the class II HDACs HDAC-4 and -5 (9) . Whereas class I HDACs are expressed relatively ubiquitously, class II HDACs, which include HDAC-4, -5, -7, and -9, are expressed in a tissuespecific manner, with highest expression in heart, brain, and skeletal muscle, where they reportedly act as signalresponsive repressors of cardiac hypertrophy (10) . Hypertrophic stimulus-induced phosphorylation of two conserved phosphorylation sites by calcium/calmodulin kinase (CaMK) causes class II HDACs to be exported from the nucleus, resulting in derepression of their target genes. In other words, nuclear export of class II HDACs induced by hypertrophic stimuli attenuates NRSF-mediated repression, thereby activating the fetal gene program in cardiac myocytes ( Fig. 1) (9) .
Transgenic mice expressing a dominant-negative NRSF mutant in their hearts exhibit dilated cardiomyopathy and sudden arrhythmic death, suggesting the NRSF-HDAC repressor complex plays a key role in the molecular pathways underlying the progression of heart failure and sudden death (8) . In dnNRSF-Tg hearts, expression of CACNA1H, which encodes the T-type Ca 2+ channel α subunit, was increased. Moreover, T-type Ca 2+ current (I ca,T ) amplitude was correspondingly increased in ventricular myocytes isolated from dnNRSF-Tg hearts, suggesting I ca,T in some way contributes to the susceptibility of dnNRSF-Tg hearts to arrhythmias (8) . Consistent with this notion, efonidipine and mibefradil, dual T-and L-type Ca 2+ channel blockers, but not nitrendipine, a more L-type-selective Ca 2+ -channel blocker, significantly improved the survival and arrhythmogenicity in dnNRSF-Tg mice (11) . The R(−)-isomer of efonidipine [R(−)-efonidipine], a recently identified, highly selective T-type Ca 2+ -channel blocker, also substantially prolonged the survival of dnNRSF-Tg mice (11, 12) . In addition, efonidipine prevented the deaths of mice with myocardial infarction, whereas nitrendipine did not. These findings demonstrate that T-type Ca 2+ -channel blockade may represent a new and effective means of preventing sudden cardiac death in patients with heart failure.
TRPC6 is a nodal point for pro-and anti-hypertrophic signaling
The serine-threonine phosphatase calcineurin (PP2B) functions as a Ca 2+ -dependent regulator of cardiac hypertrophy and the fetal gene program (13) . Calcineurin dephosphorylates nuclear factor of activated T-cells (NFAT) family transcription factors and induces their translocation to the nucleus, where they bind to the regulatory regions of cardiac genes in conjunction with other cardiac transcription factors and promote hypertrophic growth (13) . Sustained entry of Ca 2+ across the plasma membrane via agonist-or receptor-activated Ca 2+ -entry channels is thought to contribute to the activation of the calcineurin-NFAT pathway, but many of the details of the mechanisms involved in these processes remain to be elucidated. Receptor-activated Ca 2+ entry is initiated upon the binding of hormones or growth factors to Gprotein-coupled receptors or receptor tyrosine kinases, leading to activation of phospholipase C (PLC) and subsequent cleavage of phosphatidylinositol 4,5-biphosphate (PIP2) into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3) (14, 15) . Recent evidence indicates that transient receptor potential (TRP) proteins are likely channel subunits responsible for receptor-activated Ca 2+ entry (14, 16) . Initially identified in Drosophila (16) as receptor-activated cation channels (Drosophila TRP and TRP-like), 28 mammalian TRP-channel homologues have been identified to date. The mammalian TRP family has been further classified into seven subfamilies based on their structures, including canonical TRP (TRPC), vanilloid TRP (TRPV), melastatin TRP (TRPM), TRPN, TRPP, TRPML, and TRPA (14) . Structurally, the seven members of the TRPC subfamily are the most closely related to Drosophila TRP (14) . Among the TRPC channels, TRPC-3, -6 and -7 are 75% identical and gated via signal transduction pathways that activate PLC, as well as by direct exposure to DAG (17) . Thus, TRPC-3, -6, and -7 form a subfamily of second-messenger-operated cation channels coupling receptor-PLC signaling pathways to Ca 2+ entry (14) . The involvement of TRPC channels in cardiac calcineurin-NFAT signaling was examined, and it was found that expression of TRPC6 mRNA is specifically up-regulated in the hearts of mice expressing constitutively active calcineurin and subjected to pressure overload caused by transverse aortic banding (18) . The 5′-flanking region of the TRPC6 gene contains two conserved NFAT-binding sites that confer responsiveness to calcineurin-NFAT signaling. Cardiac-specific overexpression of TRPC6 in transgenic mice resulted in cardiomyopathy with a pronounced increase in the expression of β-MHC, a sensitive marker for pathological hypertrophy. Similarly, overexpression of TRPC6 in cardiomyocytes activated the NFAT-dependent promoter of the Regulator of Calcineurin 1 (RCAN1) gene and siRNA knockdown of TRPC6 reduced hypertrophic signaling by phenylephrine and endothelin-1, suggesting that TRPC6 is involved in G-protein-coupled receptor-dependent activation of the calcineurin-NFAT pathway. These findings demonstrate that TRPC6 completes a positive regulatory circuit for calcineurin-NFAT signaling during pathological cardiac remodeling and activation of fetal cardiac gene expression ( Fig. 2) (18) .
Characterization of the cross-talk among the cardiac signaling pathways that promote or antagonize hypertrophic responses should lead to a better understanding of the molecular processes underlying the establishment of cardiac hypertrophy and heart failure. We therefore investigated the signaling pathways that negatively regulate the TRPC6-calcineurin-NFAT pathway. It was recently shown that the activities of TRPC-3 and -6 are greatly attenuated by cGMP-protein kinase G (PKG)-catalyzed phosphorylation of Thr11 and Ser263 in TRPC3 and Thr69 in TRPC6, which are well conserved among mouse, rat, and human (19, 20) . We studied the functionally negative cross-talk between the antihypertrophic atrial and brain natriuretic peptide (ANP and BNP, respectively) -guanylyl cyclase-A (GC-A) -PKG pathway and the prohypertrophic TRPC6-calcineurin-NFAT pathway during the process of cardiac hypertrophy, and characterized its biological significance in cardiac pathophysiology. We found that TRPC6 is phosphorylated at Thr69 via the ANP/BNP -GC-A -PKG antihypertrophic signaling pathway, which strongly attenuated TRPC6 activity. Cardiac hypertrophy was also significantly attenuated by the selective TRPC inhibitor BTP2 in GC-A knockout (KO) mice, which were hypersensitive to hypertrophic signaling caused by overexpression of TRPC6. Likewise, BTP-2 significantly inhibited the cardiac hypertrophy induced by chronic angiotensin II infusion. Thus inhibition of TRPC6 activity contributes to the antihypertrophic effects of ANP/BNP, which suggests inhibition of TRPC6 could be an effective therapeutic strategy for preventing pathological cardiac hypertrophy and remodeling ( Fig. 2) (21) .
It has been shown in separate studies that GC-A is desensitized in failing human hearts (22) and that angiotensin II and endothelin-1 act to desensitize GC-A (23). This makes it unlikely that, under pathological conditions, endogenous cardiac ANP/BNP -GC-A -PKG signaling would be sufficient to block the pathological signaling activity. Such disruption of the balance between anti-and pro-hypertrophic signaling would lead to further activation of TRPC3/6-dependent pro-hypertrophic signaling, thereby promoting pathological cardiac remodeling. Thus inhibition of TRPC3/6 channel activity could be an effective therapeutic strategy for preventing cardiac remodeling under these conditions. Indeed, our finding that BTP2 attenuated cardiac hypertrophy in GC-A KO and angiotensin II-infused mice may support this notion. Development of highly specific TRPC6 inhibitors could lead to the production of more potent and safer agents with which to prevent pathological cardiac remodeling and heart failure.
MRTF-A is a novel transcriptional mediator linking actin remodeling and cardiac gene expression
Hemodynamic overload caused by a combination of mechanical stress and neurohumoral stimulation induces a hypertrophic response characterized in part by reactivation of the fetal gene program in cardiac myocytes (1, 24) . Among the variety of intracellular signaling molecules known to be activated following mechanical stretch or neurohumoral stimulation, Rho family small GTPases, especially Rho A and Rac1, have been highlighted as important regulators for cardiac hypertrophy (25, 26) .
A transcriptional activator, serum response factor (SRF), has been shown to be involved in the downstream mechanisms by which Rho GTPases activate the hypertrophic gene program. SRF is a MADS-box transcription factor that regulates the expression of immediate early genes and muscle-specific genes by binding to a conserved sequence [CC (A/T) 6 GG] known as the CArG box or serum response element. In this way, SRF plays an important role in the induction of a subset of cardiac genes during adverse cardiac remodeling. Targeted deletion of SRF in the developing heart results in lethal cardiac defects with reduced expression of many cardiacspecific genes (27, 28) . In addition, overexpression of SRF in the postnatal heart leads to cardiomyopathy with increased fetal cardiac gene expression (29), while conditional deletion of SRF in isolated neonatal cardiac myocytes results in reduced expression of hypertrophic genes (30) . Indeed, several fetal cardiac genes, including ANP, skeletal α-actin, smooth muscle α-actin, and smooth muscle 22α, contain a functionally important CArG box in their upstream transcription control regions (31, 32) . At least two signaling pathways are known to modulate SRF activity: one involving the phosphorylation of ternary complex factors in Ets-domain family proteins and another controlled by Rho-family small GTPases and actin dynamics (33, 34) . It was recently shown in NIH3T3 cells that stimulation of Rho-and actin dynamics-dependent signaling results in translocation of a novel SRF co-factor, myocardin-related transcription factor (MRTF)-A (also known as MAL or MKL1), from G-actin in the cytoplasm to the nucleus, leading to activation of SRF target genes (35, 36) .
We further showed that Rho-and actin treadmill-dependent nuclear accumulation of MRTF-A contributes to the transduction of mechanical stress to SRF-dependent transcriptional activation of fetal cardiac genes in cardiac myocytes. In mice lacking MRTF-A, induction of BNP and other fetal cardiac genes in response to both acute and chronic pressure overload was significantly attenu-ated. We also revealed the involvement of MRTF-A in chronic cardiac remodeling, a process in which neurohumoral factors play a pivotal role. Following stimulation with angiotensin II or endothelin-1, MRTF-A was translocated into the nuclei of cardiac myocytes, where it activated SRF. Moreover, MRTF-A −/− mice showed significantly weaker hypertrophic responses than their wild-type littermates. Collectively, these findings indicate that MRTF-A is a common mediator of mechanical stressand neurohumoral stimulation-induced prohypertrophic signaling ( Fig. 3) (37) .
The inhibition of Rho or ROCK (Rho kinase), a downstream target of Rho, ameliorates pathological cardiac hypertrophy (25, 38, 39) . Our study defines MRTF-A as a critical downstream mediator of Rho-and actin dynamics-associated prohypertrophic signaling in cardiac myocytes, while others have shown that in epithelial cells MRTF-A is also activated downstream of Rac (40) . Two important events that occur downstream of Rho and Rac activation are alteration of actin cytoskeletal organization and gene transcription, and MRTF-A is a key mediator of the latter. Consequently, diminishing MRTF-A-mediated transcriptional activation by inhibiting its nuclear translocation and/or its co-activator function, which would selectively block transcriptional pathways activated downstream of Rho family small GTPases, could be a safer and more specific therapeutic approach to preventing pathological cardiac remodeling, without the potential side effects caused by disruption of the physiological organization of the actin-cytoskeleton ( Fig.  3) . 
Conclusion
Genetic remodeling contributes to the progression of heart failure by affecting myocardial cellular function and survival. Exploring the transcriptional pathways involved in pathological cardiac remodeling will lead to a better understanding of the molecular mechanisms underlying the development of pathological processes in the heart and will ultimately provide us with an opportunity to shed light on new molecular effectors with the potential to have a therapeutic impact on human heart failure. In this mini-review, we have introduced our work on the transcriptional pathways involved in pathological cardiac remodeling. A transcriptional repressor, NRSF, represses expression of multiple fetal cardiac genes through recruitment of HDACs, and attenuation of this NRSF-mediated repression appears to contribute to the re-expression of fetal cardiac genes in diseased hearts. Inhibition of NRSF in the heart results in cardiac dysfunction and sudden arrhythmic death accompanied by re-expression of multiple fetal genes, including those encoding fetal ion channels, such as the T-type Ca 2+ channel. Conversely, T-type Ca 2+ -channel blockade significantly prolongs survival in dnNRSF-Tg mice (12) . TRPC6 is a key integrated component of the calcineurin-NFAT signaling circuit, and its inhibition significantly ameliorates the pathological process in mouse models of cardiac hypertrophy. This at least in part reflects the fact that inhibition of TRPC6 contributes to the antihypertrophic effects exerted by ANP/BNP -GC-A -PKG signaling, which suggests TRPC6 blockade could be a novel therapeutic strategy for preventing pathological cardiac remodeling. Finally, we revealed a new signaling mechanism whereby MRTF-A, a co-activator of SRF, mediates both mechanical stress-and neurohumoral stimulationinduced prohypertrophic signaling by linking the small GTPase Rho-actin dynamics signaling pathway to cardiac gene transcription. Collectively, our studies on the transcriptional network underlying the pathological cardiac remodeling have revealed several potential therapeutic targets; T-type Ca 2+ channel, TRPC6 channel, and MRTF-A. We anticipate that further study of the transcriptional network involved in the development of cardiac dysfunction will lead to the discovery of new therapeutic targets for the treatment of heart failure.
